Celgene’s $710M deal on mongersen implodes as Phase III Crohn's study flops
Celgene’s $710 million cash roll of the dice on the inflammatory bowel disease drug mongersen (GED-301) has come up snake eyes.
The big biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
